The Experts below are selected from a list of 630 Experts worldwide ranked by ideXlab platform

Dong-yeop Shin - One of the best experts on this subject based on the ideXlab platform.

  • increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera
    Clinical Hemorheology and Microcirculation, 2018
    Co-Authors: Dong-woo Shin, Jae Seol Jung, Ja Yoon Gu, Dong-yeop Shin
    Abstract:

    BACKGROUND: Although Hyperviscosity Syndrome in plasma cell dyscrasia (PCD) and thrombosis in myeloproliferative neoplasm (MPN) are major causes of morbidity and mortality, blood viscosity measurements are often underutilized. OBJECTIVE: This study aimed to characterize whether whole blood viscosity (WBV) or plasma viscosity (PV) could be predictive of Hyperviscosity Syndrome in PCD and could be elevated in subgroups of MPN. METHODS: A total of 75 patients with hematologic diseases: PCD (n = 26), MPN (n = 25) including polycythemia vera (P. vera) and lymphoma (n = 24) were enrolled along with 104 healthy controls. Both WBV and PV were measured using a capillary tube viscometer. Hyperviscosity Syndrome was defined as having 2 or more Hyperviscosity symptoms. RESULTS: Patients with PCD showed significantly higher PVs at high and low shear rates when compared to healthy controls, especially in those with Hyperviscosity Syndrome. The sensitivity and specificity of WBV and PV in detecting Hyperviscosity Syndrome were 28.6% and 94.1%, and 71.4% and 66.7%, respectively. Patients with P. vera exhibited high WBV and RBC counts compared to healthy controls. CONCLUSION: PV is predictive of Hyperviscosity Syndrome in PCD and WBV is elevated in patients with P. vera. It suggests that hemorheologic disturbances exist in patients with PCD and MPN and that tests of viscosity may be helpful in detecting hemorheological disturbances.

  • increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera
    Clinical Hemorheology and Microcirculation, 2018
    Co-Authors: Dong-woo Shin, Jae Seol Jung, Ja Yoon Gu, Dong-yeop Shin
    Abstract:

    BACKGROUND: Although Hyperviscosity Syndrome in plasma cell dyscrasia (PCD) and thrombosis in myeloproliferative neoplasm (MPN) are major causes of morbidity and mortality, blood viscosity measurements are often underutilized. OBJECTIVE: This study aimed to characterize whether whole blood viscosity (WBV) or plasma viscosity (PV) could be predictive of Hyperviscosity Syndrome in PCD and could be elevated in subgroups of MPN. METHODS: A total of 75 patients with hematologic diseases: PCD (n = 26), MPN (n = 25) including polycythemia vera (P. vera) and lymphoma (n = 24) were enrolled along with 104 healthy controls. Both WBV and PV were measured using a capillary tube viscometer. Hyperviscosity Syndrome was defined as having 2 or more Hyperviscosity symptoms. RESULTS: Patients with PCD showed significantly higher PVs at high and low shear rates when compared to healthy controls, especially in those with Hyperviscosity Syndrome. The sensitivity and specificity of WBV and PV in detecting Hyperviscosity Syndrome were 28.6% and 94.1%, and 71.4% and 66.7%, respectively. Patients with P. vera exhibited high WBV and RBC counts compared to healthy controls. CONCLUSION: PV is predictive of Hyperviscosity Syndrome in PCD and WBV is elevated in patients with P. vera. It suggests that hemorheologic disturbances exist in patients with PCD and MPN and that tests of viscosity may be helpful in detecting hemorheological disturbances.

Huan-you Wang - One of the best experts on this subject based on the ideXlab platform.

  • Fatal Cerebral Hemorrhage in a Patient with CD19positive IgM-producing Aggressive Plasma Cell Myeloma, Hyperviscosity Syndrome and Cryoglobulinemia
    2014
    Co-Authors: Adnan Alatoom, Rania Elsabrouty, Jason Willis, Christie Boils, Ravindra Sarode, Ibrahim Hashim, Huan-you Wang
    Abstract:

    Here we report a unique case of IgM PCM, in which the plasma cells are positive for CD19. Clinically, the patient presented with Hyperviscosity Syndrome, mimicking the clinical manifestation of Waldenstrom’s macroglobulinemia. In addition, the IgM para-protein from the patient behaved like cryoglobulins, which interfered with some of the laboratory measurements and resulted in erroneous platelet count, mean platelet volume, and serum IgM level. Despite chemotherapy, the PCM persisted and progressed to plasma cell leukemia, and the patient died of a left frontal hematoma with widespread cerebral hemorrhage extending from left lateral ventricle, third ventricle, fourth ventricle, to cisterna magna. This case represents the first CD19+ IgM-producing PCM and the second case of brain hemorrhage due to plasma cell myeloma/leukemia

  • fatal cerebral hemorrhage in a patient with cd19 positive igm producing aggressive plasma cell myeloma Hyperviscosity Syndrome and cryoglobulinemia
    International Journal of Clinical and Experimental Pathology, 2009
    Co-Authors: Adnan Alatoom, Rania Elsabrouty, Jason Willis, Christie Boils, Ravindra Sarode, Ibrahim A Hashim, Huan-you Wang
    Abstract:

    IgM plasma cell myeloma (PCM) is a rare entity, and CD19 positivity is found in only 1–4% of PCM. Here we report a unique case of IgM PCM, in which the plasma cells are positive for CD19. Clinically, the patient presented with Hyperviscosity Syndrome, mimicking the clinical manifestation of Waldenstrom's macroglobulinemia. In addition, the IgM para-protein from the patient behaved like cryoglobulins, which interfered with some of the laboratory measurements and resulted in erroneous platelet count, mean platelet volume, and serum IgM level. Despite chemotherapy, the PCM persisted and progressed to plasma cell leukemia, and the patient died of a left frontal hematoma with widespread cerebral hemorrhage extending from left lateral ventricle, third ventricle, fourth ventricle, to cisterna magna. This case represents the first CD19+ IgM-producing PCM and the second case of brain hemorrhage due to plasma cell myeloma/leukemia.

Dong-woo Shin - One of the best experts on this subject based on the ideXlab platform.

  • increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera
    Clinical Hemorheology and Microcirculation, 2018
    Co-Authors: Dong-woo Shin, Jae Seol Jung, Ja Yoon Gu, Dong-yeop Shin
    Abstract:

    BACKGROUND: Although Hyperviscosity Syndrome in plasma cell dyscrasia (PCD) and thrombosis in myeloproliferative neoplasm (MPN) are major causes of morbidity and mortality, blood viscosity measurements are often underutilized. OBJECTIVE: This study aimed to characterize whether whole blood viscosity (WBV) or plasma viscosity (PV) could be predictive of Hyperviscosity Syndrome in PCD and could be elevated in subgroups of MPN. METHODS: A total of 75 patients with hematologic diseases: PCD (n = 26), MPN (n = 25) including polycythemia vera (P. vera) and lymphoma (n = 24) were enrolled along with 104 healthy controls. Both WBV and PV were measured using a capillary tube viscometer. Hyperviscosity Syndrome was defined as having 2 or more Hyperviscosity symptoms. RESULTS: Patients with PCD showed significantly higher PVs at high and low shear rates when compared to healthy controls, especially in those with Hyperviscosity Syndrome. The sensitivity and specificity of WBV and PV in detecting Hyperviscosity Syndrome were 28.6% and 94.1%, and 71.4% and 66.7%, respectively. Patients with P. vera exhibited high WBV and RBC counts compared to healthy controls. CONCLUSION: PV is predictive of Hyperviscosity Syndrome in PCD and WBV is elevated in patients with P. vera. It suggests that hemorheologic disturbances exist in patients with PCD and MPN and that tests of viscosity may be helpful in detecting hemorheological disturbances.

  • increased plasma viscosity in plasma cell dyscrasia and whole blood viscosity in polycythemia vera
    Clinical Hemorheology and Microcirculation, 2018
    Co-Authors: Dong-woo Shin, Jae Seol Jung, Ja Yoon Gu, Dong-yeop Shin
    Abstract:

    BACKGROUND: Although Hyperviscosity Syndrome in plasma cell dyscrasia (PCD) and thrombosis in myeloproliferative neoplasm (MPN) are major causes of morbidity and mortality, blood viscosity measurements are often underutilized. OBJECTIVE: This study aimed to characterize whether whole blood viscosity (WBV) or plasma viscosity (PV) could be predictive of Hyperviscosity Syndrome in PCD and could be elevated in subgroups of MPN. METHODS: A total of 75 patients with hematologic diseases: PCD (n = 26), MPN (n = 25) including polycythemia vera (P. vera) and lymphoma (n = 24) were enrolled along with 104 healthy controls. Both WBV and PV were measured using a capillary tube viscometer. Hyperviscosity Syndrome was defined as having 2 or more Hyperviscosity symptoms. RESULTS: Patients with PCD showed significantly higher PVs at high and low shear rates when compared to healthy controls, especially in those with Hyperviscosity Syndrome. The sensitivity and specificity of WBV and PV in detecting Hyperviscosity Syndrome were 28.6% and 94.1%, and 71.4% and 66.7%, respectively. Patients with P. vera exhibited high WBV and RBC counts compared to healthy controls. CONCLUSION: PV is predictive of Hyperviscosity Syndrome in PCD and WBV is elevated in patients with P. vera. It suggests that hemorheologic disturbances exist in patients with PCD and MPN and that tests of viscosity may be helpful in detecting hemorheological disturbances.

Adnan Alatoom - One of the best experts on this subject based on the ideXlab platform.

  • Fatal Cerebral Hemorrhage in a Patient with CD19positive IgM-producing Aggressive Plasma Cell Myeloma, Hyperviscosity Syndrome and Cryoglobulinemia
    2014
    Co-Authors: Adnan Alatoom, Rania Elsabrouty, Jason Willis, Christie Boils, Ravindra Sarode, Ibrahim Hashim, Huan-you Wang
    Abstract:

    Here we report a unique case of IgM PCM, in which the plasma cells are positive for CD19. Clinically, the patient presented with Hyperviscosity Syndrome, mimicking the clinical manifestation of Waldenstrom’s macroglobulinemia. In addition, the IgM para-protein from the patient behaved like cryoglobulins, which interfered with some of the laboratory measurements and resulted in erroneous platelet count, mean platelet volume, and serum IgM level. Despite chemotherapy, the PCM persisted and progressed to plasma cell leukemia, and the patient died of a left frontal hematoma with widespread cerebral hemorrhage extending from left lateral ventricle, third ventricle, fourth ventricle, to cisterna magna. This case represents the first CD19+ IgM-producing PCM and the second case of brain hemorrhage due to plasma cell myeloma/leukemia

  • fatal cerebral hemorrhage in a patient with cd19 positive igm producing aggressive plasma cell myeloma Hyperviscosity Syndrome and cryoglobulinemia
    International Journal of Clinical and Experimental Pathology, 2009
    Co-Authors: Adnan Alatoom, Rania Elsabrouty, Jason Willis, Christie Boils, Ravindra Sarode, Ibrahim A Hashim, Huan-you Wang
    Abstract:

    IgM plasma cell myeloma (PCM) is a rare entity, and CD19 positivity is found in only 1–4% of PCM. Here we report a unique case of IgM PCM, in which the plasma cells are positive for CD19. Clinically, the patient presented with Hyperviscosity Syndrome, mimicking the clinical manifestation of Waldenstrom's macroglobulinemia. In addition, the IgM para-protein from the patient behaved like cryoglobulins, which interfered with some of the laboratory measurements and resulted in erroneous platelet count, mean platelet volume, and serum IgM level. Despite chemotherapy, the PCM persisted and progressed to plasma cell leukemia, and the patient died of a left frontal hematoma with widespread cerebral hemorrhage extending from left lateral ventricle, third ventricle, fourth ventricle, to cisterna magna. This case represents the first CD19+ IgM-producing PCM and the second case of brain hemorrhage due to plasma cell myeloma/leukemia.

Seema Singhal - One of the best experts on this subject based on the ideXlab platform.

  • Hyperviscosity Syndrome in plasma cell dyscrasias.
    Seminars in Thrombosis and Hemostasis, 2003
    Co-Authors: Jayesh Mehta, Seema Singhal
    Abstract:

    Hypergammaglobulinemia increases serum viscosity and is the most common cause of Hyperviscosity Syndrome. Monoclonal hypergammaglobulinemia resulting in Hyperviscosity Syndrome is seen in multiple myeloma and Waldenstrom's macroglobulinemia. The reasons for elevated viscosity are increased protein content and large molecular size, abnormal polymerization, and abnormal shape of immunoglobulin molecules. Other hematologic and metabolic abnormalities seen in patients with plasma cell dyscrasias also contribute to Hyperviscosity. Symptomatic Hyperviscosity is much more common in Waldenstrom's macroglobulinemia (10 to 30%) than it is in myeloma (2 to 6%). Symptoms of Hyperviscosity usually appear when the normal serum viscosity of 1.4 to 1.8 cp reaches 4 to 5 cp, corresponding to a serum immunoglobulin M (IgM) level of at least 3 g/dL, an IgG level of 4 g/dL, and an IgA level of 6 g/dL. Symptoms of Hyperviscosity include constitutional symptoms; bleeding; and ocular, neurological, and cardiovascular manifestations. Immediate therapy of symptomatic Hyperviscosity is directed at reduction of blood viscosity by plasmapheresis to control symptoms. Long-term management is directed at control of the underlying disease to prevent production of the monoclonal protein. There may be a small proportion of individuals, usually old or with severely compromised performance status, who undergo plasma exchange as the sole symptomatic therapy of Hyperviscosity secondary to plasma cell dyscrasia.